Evidence map›Paper›PMID 30621107›Full record

ArticleLife (Basel, Switzerland)2019

Real-World Synthetic Biology: Is It Founded on an Engineering Approach, and Should It Be?

Jamie A Davies

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Synthetic Biology─High Time to Deliver?ACS synthetic biology · 2023
    Article
  4. Article
  5. Synthetic Morphogenesis: introducing IEEE journal readers to programming living mammalian cells to make structures.Proceedings of the IEEE. Institute of Electrical and Electronics Engineers · 2022
    Article
  6. Review
  7. Cell-Free Systems: A Proving Ground for Rational Biodesign.Frontiers in bioengineering and biotechnology · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jamie A DaviesUK Centre for Mammalian Synthetic Biology, University of Edinburgh, Edinburgh EH8 9YL, UK. jamie.davies@ed.ac.uk.
University of Edinburgh · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M018040/1
6 · The paper itself

Abstract

Authors often assert that a key feature of 21st-century synthetic biology is its use of an 'engineering approach'; design using predictive models, modular architecture, construction using well-characterized standard parts, and rigorous testing using standard metrics. This article examines whether this is, or even should be, the case. A brief survey of synthetic biology projects that have reached, or are near to, commercial application outside laboratories shows that they showed very few of these attributes. Instead, they featured much trial and error, and the use of specialized, custom components and assays. What is more, consideration of the special features of living systems suggest that a conventional engineering approach will often not be helpful. The article concludes that the engineering approach may be useful in some projects, but it should not be used to define or constrain synthetic biological endeavour, and that in fact the conventional engineering has more to gain by expanding and embracing more biological ways of working.

Indexed as

abstractionassaydesignmodellingmodularitystandardization

Identifiers

PMID30621107
PMCPMC6463249
OpenAlexW2908276169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.